Journal of Cancer Research
- ISSN: 2578-3726
Alexandre Tavartkiladze, Gaiane Simonia, Tolga Sutlu, Nana Okrostsvaridze and Givi Tavartkiladze
Background: Prolonged SARS-CoV-2 infection has been associated with significant biochemical and genetic alterations, leading to a range of long-term health complications. This study aims to elucidate these alterations and assess the therapeutic potential of Soulager in mitigating associated risks.
Methods: A cohort of 55 individuals aged 17-77 years was divided into two groups: those with a history of SARS-CoV-2 infection and a control group without infection. Various parameters, including CD4+/CD8+ ratios, lipid profiles, endothelial markers, cytokine levels, and oxidative stress markers, were measured. Biochemical and genetic analyses were conducted using qPCR, ELISA, ECLIA, HPLC, and flow cytometry. The intervention group received Soulager 9 capsules (3 times a day for 30 days), and changes in biochemical and genetic markers were monitored.
Results: Baseline characteristics showed significant immunosuppression and endothelial damage in the SARS-CoV-2 infected group compared to controls. Elevated levels of triglycerides, LDL, VLDL, and Atherogenic Index of Plasma (AIP) and decreased HDL levels were observed in the infected group. Soulager administration resulted in a 35% reduction in IL-6, a 40% reduction in TNF-α, a 25% reduction in homocysteine levels, and significant improvements in lipid profiles and endothelial function. These changes correlated with a decreased risk of cardiovascular and oncological events.
Discussion: The results highlight the mechanisms through which SARS-CoV-2 affects lipid metabolism, immune function, and endothelial health. Chronic inflammation and oxidative stress were identified as key drivers of these alterations. The findings align with existing literature on long-term COVID-19 effects and suggest potential interventions to mitigate these risks.
Conclusion: The study underscores the importance of early detection and intervention in managing long-term effects of COVID-19. Soulager demonstrated significant efficacy in correcting biochemical parameters and reducing oncological and cardiological risks. Ongoing research is essential to fully understand and combat the long-term consequences of SARSCoV-2 infection, and therapeutics like Soulager offer promising avenues for improving patient outcomes.